Pirtobrutinib and BTK Inhibitors in the CLL Treatment Landscape
Pharmacy Times,
Image credit: jarun011 | stock.adobe.com Précis This review discusses the prevalence, mechanisms of development, and evolving…
Image credit: jarun011 | stock.adobe.com Précis This review discusses the prevalence, mechanisms of development, and evolving…
A small proportion of a subset of patients with chronic lymphocytic leukemia acquired mechanisms of genetic resistance to the…
Data Support ARQ 531 as a Potential First- and Best-In-Class Reversible BTK Inhibitor, with the Potential to Address Emerging…
ArQule, Inc. (Nasdaq:ARQL), today announced the publication of preclinical study data for ARQ 531, the Company’s rationally-desig…